U.S. Markets closed

Allergan price target raised to $118 from $104 at Argus

Argus increased its target on Allergan as the firm believes that the company reported solid sales and earnings growth ,and has a strong pipeline. The firm expects the company to generate double digit earnings growth over the next three to five years, driven by several positive catalysts. It maintains a Buy rating on the shares.